Key Market Trends and Developments:
- COVID-19 Pandemic Impact:The success of mRNA vaccines during the COVID-19 pandemic has accelerated research and development in mRNA technology for both vaccines and therapeutics.
- Increased Focus on Infectious Disease Preparedness:The pandemic has highlighted the need for rapid development of mRNA-based vaccines and therapeutics, leading to increased investment in platforms for future outbreaks.
- Strategic Partnerships and Acquisitions:Companies are forming strategic partnerships and acquiring smaller companies to leverage expertise and technologies in RNA-based therapeutics.
- Advancements in Delivery Systems:Research is focused on improving the delivery of RNA-based therapies to target specific tissues and cells more effectively, including the development of peptide-siRNA conjugates.
- Growing Number of Clinical Trials:There is a significant increase in the number of clinical trials for RNA-based therapies across various disease areas, including genetic disorders, infectious diseases, and oncology.
- Government Funding and Initiatives:Governments are investing in large-scale sequencing projects and supporting the development of RNA-based therapeutics through various initiatives.
RNA Based Therapeutic Market Segment
Based on type, the RNA antisense segment accounted for the largest share in 2020, contributing to nearly two-thirds of the global RNA based therapeutics market revenue, and is expected to retain its lion’s share throughout the forecast period. Due to the rise in revenue generated from the development and commercialization of RNA antisense drugs and therapeutics. However, the RNA interference (RNAi) segment would display the fastest CAGR of 18.8% from 2021 to 2030.
The genetic disorder segment to rule the roost by 2030-
Based on application, the genetic disorder segment held the major market share in 2020, accounting for more than three-fifths of the global RNA based therapeutics market revenue, and is projected to rule the roost by 2030. The same segment would showcase the highest CAGR of 18.2% from 2021 to 2030. Due to an increase in the incidence of rare diseases, genetic disorders, and molecular diagnosis. The autoimmune disorder segment is also studied in the report.
Recent Developments in the RNA Based Therapeutics Market
- In June 2022, Alnylam Pharmaceuticals, Inc., one of the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA (vutrisiran), an RNAi therapeutic administered via subcutaneous injection once every three months (quarterly) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
- In December 2021, Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, and Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, announced that the companies have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of AB-729 for the treatment of hepatitis B. AB-729 is Arbutus’s lead RNA interference (RNAi) therapeutic that is currently in multiple Phase 2a proof-of-concept clinical trials designed to evaluate it in combination with other approved or investigational agents.
Leading Companies in the Market:
- Alnylam Pharmaceuticals, Inc.
- Moderna
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals
- Novartis
- Sanofi (Genzyme)
- Eli Lilly and Company
- Janssen Pharmaceuticals
- Dicerna Pharmaceuticals
- OliX Pharmaceuticals
- ProQR Therapeutics
- Fujian Shengdi Pharmaceutical
- Silence Therapeutics
- Translate Bio
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the market analysis from 2021 to 2031 to identify the prevailing RNA Based Therapeutic Market Opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the market segmentation assists to determine the prevailing RNA Based Therapeutic Market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global RNA Based Therapeutic Market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the RNA Based Therapeutic Market players.
- The report includes the analysis of the regional as well as global trends, key players, market segments, application areas, and market growth strategies.
Read More:
Scientific Instruments Market https://www.newstrail.com/scientific-instruments-market/
Blood Stream Infection Testing Market https://www.newstrail.com/blood-stream-infection-testing-market/
Contact Details:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
